Roche

Alvleesklierkanker

• Ocrelizumab

  Status

  Gepubliceerd

• Tocilizumab

  Status

  Gepubliceerd

Huidkanker

• Vemurafenib

• Treatment (monotherapy) of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy. Patients with EGFR activating mutations or ALK-positive tumour mutations should also have received targeted therapy before receiving atezolizumab

  Status

  Gepubliceerd

• Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam, eaque ipsa quae ab illo inventore veritatis et quasi architecto beatae vitae dicta sunt explicabo.

  Status

  Gepubliceerd

Longkanker

• Alectinib

  Status

  Gepubliceerd

• Atezolizumab

• Treatment (monotherapy) of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy. Patients with EGFR activating mutations or ALK-positive tumour mutations should also have received targeted therapy before receiving atezolizumab

  Status

  Gepubliceerd

• NSCLC, 2e behandeling

  Status

  Gepubliceerd

Blaaskanker

• Atezolizumab

  Status

  Gepubliceerd

Lymfeklierkanker

• Obinutuzumab

  Status

  Gepubliceerd

Borstkanker

• Atezolizumab

• Indication couldn't be found

  Status

  Gepubliceerd

• Tecentriq in combination with nab-paclitaxel is indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) whose tumours have PD-L1 expression ≥ 1% and who have not received prior chemotherapy for metastatic disease.

  Status

  Gepubliceerd

• Pertuzumab

  Status

  Gepubliceerd

Maagkanker